DE60236858D1 - Blut - Google Patents

Blut

Info

Publication number
DE60236858D1
DE60236858D1 DE60236858T DE60236858T DE60236858D1 DE 60236858 D1 DE60236858 D1 DE 60236858D1 DE 60236858 T DE60236858 T DE 60236858T DE 60236858 T DE60236858 T DE 60236858T DE 60236858 D1 DE60236858 D1 DE 60236858D1
Authority
DE
Germany
Prior art keywords
cells
blood
suppressive
regulative
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60236858T
Other languages
English (en)
Inventor
Gerold Schuler
Detlef Dieckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merix Bioscience Inc
Original Assignee
Merix Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60236858(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merix Bioscience Inc filed Critical Merix Bioscience Inc
Application granted granted Critical
Publication of DE60236858D1 publication Critical patent/DE60236858D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002Partitioning blood components
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/46434Antigens related to induction of tolerance to non-self
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/12Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14Calcium; Ca chelators; Calcitonin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60236858T 2001-03-12 2002-03-12 Blut Expired - Lifetime DE60236858D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106033A EP1241249A1 (de) 2001-03-12 2001-03-12 Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
PCT/EP2002/002671 WO2002072799A1 (en) 2001-03-12 2002-03-12 Cd4+cd25+ regulatory t cells from human blood

Publications (1)

Publication Number Publication Date
DE60236858D1 true DE60236858D1 (de) 2010-08-12

Family

ID=8176748

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60236858T Expired - Lifetime DE60236858D1 (de) 2001-03-12 2002-03-12 Blut

Country Status (10)

Country Link
EP (2) EP1241249A1 (de)
JP (3) JP2004529631A (de)
KR (3) KR101301923B1 (de)
CN (2) CN101385742A (de)
AT (1) ATE472598T1 (de)
AU (2) AU2002257648B2 (de)
BR (1) BR0208076A (de)
CA (1) CA2441213C (de)
DE (1) DE60236858D1 (de)
WO (1) WO2002072799A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999048524A1 (en) 1998-03-03 1999-09-30 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
CA2469800A1 (en) * 2001-12-21 2003-07-24 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20030147865A1 (en) * 2002-02-07 2003-08-07 Benoit Salomon Cell therapy using immunoregulatory T-cells
US7479123B2 (en) 2002-03-04 2009-01-20 Therakos, Inc. Method for collecting a desired blood component and performing a photopheresis treatment
US7211037B2 (en) 2002-03-04 2007-05-01 Therakos, Inc. Apparatus for the continuous separation of biological fluids into components and method of using same
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1391210A3 (de) * 2002-08-12 2007-10-31 Gerold Schuler Regulatorisches Medikament enthaltend CD4+CD25- T Zellen und Tr1-analoge regulatorische Zellen
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0302167D0 (en) * 2003-01-30 2003-03-05 Leuven K U Res & Dev T cell phenotype
EP1460088A1 (de) * 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US7651855B2 (en) 2003-04-17 2010-01-26 The Trustees Of The University Of Pennsylvania Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses
JP5097400B2 (ja) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
FR2864546A1 (fr) * 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
CA2568344C (en) * 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
JP2007320852A (ja) * 2004-10-22 2007-12-13 Kyoto Univ 肝障害の予防又は治療方法
DE102005002110A1 (de) * 2005-01-17 2006-07-27 Protagen Ag Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen
WO2006081620A1 (en) * 2005-02-02 2006-08-10 Newsouth Innovations Pty Limited Cd4+ cd25+ t-cells activated to a specific antigen
WO2006111986A1 (en) * 2005-04-19 2006-10-26 Fondazione Santa Lucia I.R.C.C.S. Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof
WO2006133398A2 (en) * 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
US8916147B2 (en) 2005-08-24 2014-12-23 Yeda Research and Devolpment Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
CN101313062A (zh) 2005-09-23 2008-11-26 塞勒里克斯有限公司 具有免疫调节活性的细胞群及其分离方法和用途
GB0604170D0 (en) * 2006-03-02 2006-04-12 Antitope Ltd T cell assays
PT1989544E (pt) * 2006-03-02 2011-09-26 Antitope Ltd Ensaios com células t
FR2898275B1 (fr) * 2006-03-10 2012-12-14 Genethon Cellules t regulatrices cd4+cd25+specifiques pour la greffe de cellules hematopoietiques et la tolerance immunitaire
US8569059B2 (en) 2006-08-02 2013-10-29 Newsouth Innovations Pty Limited Method of identifying CD4+ CD25+ T-cells activated to an antigen which express CD8
JP5867795B2 (ja) 2007-02-01 2016-02-24 テーツェーエフ ゲゼルシャフト ミット ベシュレンクテル ハフツング 調節性t細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用
KR20100135808A (ko) 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
AU2009235622C9 (en) 2008-03-13 2015-07-02 Biotest Ag Agent for treating disease
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2595637B1 (de) 2010-07-22 2017-11-01 Cellect Biotherapeutics Ltd. Immunregulatorische zellen mit verstärkter gezielter zelltodwirkung
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) 赤血球結合療法
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20140212398A1 (en) * 2011-09-08 2014-07-31 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
WO2015003240A1 (en) 2013-07-12 2015-01-15 Canadian Blood Services Acellular pro-inflammatory compositions, process for making same and methods of using same
CN103464691A (zh) * 2013-09-26 2013-12-25 北京北方车辆集团有限公司 主动轮齿盘毛坯的铸造方法
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10561685B2 (en) 2014-07-10 2020-02-18 Canadian Bllood Services Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
CN106566806B (zh) * 2016-07-11 2018-05-04 英威福赛生物技术有限公司 体外培养富集cd8+t细胞的方法
KR101885221B1 (ko) * 2016-10-25 2018-08-06 (주)에이온엘에스 말초혈액단핵구 유래 조절 t 세포 배양용 배지 조성물 및 이를 이용한 조절 t 세포 배양방법
EP3551749B1 (de) 2016-12-07 2023-09-27 East Carolina University Zusammensetzungen und verfahren zur in vitro-kultivierung und/oder expansion von regulatorischen t-zellen
CN108084263B (zh) * 2016-12-16 2021-07-13 苏州旭光科星抗体生物科技有限公司 一种抗人cd25嵌合单克隆抗体及其制备方法和应用
CN107083360B (zh) * 2017-05-23 2019-07-05 华中科技大学同济医学院附属同济医院 一种体外诱导扩增人抗原非特异性调节性t细胞的方法
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
TWI699218B (zh) * 2017-12-22 2020-07-21 財團法人工業技術研究院 體外活化及/或擴增免疫細胞的方法
CN108588021A (zh) * 2018-05-02 2018-09-28 深圳市因诺转化医学研究院 分离和纯化til、获取cd4+cd25+细胞亚群的方法
CN108588022B (zh) * 2018-05-10 2019-12-10 英威福赛生物技术有限公司 体外培养富集人cd4+和cd8+ tcm细胞的方法
CN114480279A (zh) * 2022-01-18 2022-05-13 吉林省真承药业有限公司 一种高效的人类血液免疫细胞cd4t分离培养技术

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673499B2 (en) * 1991-07-25 1996-11-14 Biogen Idec Inc. Recombinant antibodies for human therapy
CA2291338A1 (en) * 1997-06-11 1998-12-17 Wisconsin Alumni Research Foundation Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
ATE332963T1 (de) * 1999-01-22 2006-08-15 Schepens Eye Res Inst Aktivierung von regulatorischen t zellen durch ein alpha-melanocyten stimulierendes hormon
WO2001016296A2 (en) * 1999-09-01 2001-03-08 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut

Also Published As

Publication number Publication date
KR20090126329A (ko) 2009-12-08
JP2011041570A (ja) 2011-03-03
EP1241249A1 (de) 2002-09-18
KR20110047279A (ko) 2011-05-06
WO2002072799A1 (en) 2002-09-19
KR101301923B1 (ko) 2013-08-30
ATE472598T1 (de) 2010-07-15
AU2002257648B2 (en) 2008-01-17
BR0208076A (pt) 2004-03-02
CA2441213A1 (en) 2002-09-19
AU2008201685A1 (en) 2008-05-08
CN101385742A (zh) 2009-03-18
CN1509327A (zh) 2004-06-30
CN1509327B (zh) 2010-10-20
KR20030088037A (ko) 2003-11-15
JP2009060894A (ja) 2009-03-26
AU2008201685B2 (en) 2011-03-31
JP2004529631A (ja) 2004-09-30
EP1379625B1 (de) 2010-06-30
CA2441213C (en) 2014-01-07
EP1379625A1 (de) 2004-01-14
JP4714767B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
DE60236858D1 (de) Blut
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
ATE487504T1 (de) Zusammensetzungen und verfahren für biomedizinische anwendungen
BR0215405A (pt) Composições e processos de uso de collajolie
ATE531340T1 (de) Ballon-expandierbarer stent und herstellungsverfahren dafür
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
DE602004019917D1 (de) Bandscheibenimplantate und methoden zu deren herstellung
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
HUP0402029A2 (hu) Peptidalapú multimer célzott kontrasztanyagok
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
ATE337817T1 (de) Medizinisches gerät
DE60105532D1 (de) Expandiertes Polytetrafluoroethylen für medizinische Anwendungen
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
WO2005043967A8 (en) Z-axis assembly of medical device programmer
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
CY1108747T1 (el) Παρασκευες ενος σουλφινυλο ακεταμιδιου
AU2003230173A1 (en) A working tool for accurate lateral resection of biological tissue and a method for use thereof
MXPA03007142A (es) Derivados de carbolina.
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
NO20044898L (no) Nye etonogestrel estere
DE60325377D1 (de) Motilidverbindungen
MXPA04003755A (es) Endoprotesis vasculares.
WO2003084384A3 (en) Diagnosis of flavivirus infection
ATE399532T1 (de) Medizinische seife

Legal Events

Date Code Title Description
8363 Opposition against the patent